S. Stanisic, A. Cicchetti, C. Porta, G. Procopio, and P. Berto, “Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy”, Grhta, vol. 5, no. 1, Jul. 2018.